Patents by Inventor Marc Learned

Marc Learned has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell-based drug screens for regulators of gene expression
    Patent number: 7105313
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: September 12, 2006
    Assignee: Amgen Inc.
    Inventors: Bei Shan, R. Marc Learned, M. Catherine Amaral, Steven L. McKnight, Fabienne C. de la Brousse, Jin-Long Chen
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Publication number: 20060134681
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Application
    Filed: December 22, 2005
    Publication date: June 22, 2006
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Patent number: 7026122
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 11, 2006
    Assignee: PTC Therapeutics, Inc.
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski
  • Cell-based drug screens for regulators of gene expression
    Publication number: 20030153025
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.
    Type: Application
    Filed: February 13, 2003
    Publication date: August 14, 2003
    Applicant: Tularik, Inc.
    Inventors: Bei Shan, R. Marc Learned, M. Catherine Amaral, Steven L. McKnight, Fabienne Charles de la Brousse, Jin-Long Chen
  • Cell-based drug screens for regulators of gene expression
    Patent number: 6566089
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.
    Type: Grant
    Filed: May 31, 1997
    Date of Patent: May 20, 2003
    Assignee: Tularik Inc.
    Inventors: Bei Shan, R. Marc Learned, M. Catherine Amaral, Steven L. McKnight, Fabienne Charles de la Brousse, Jin-Long Chen
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Publication number: 20030008317
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Application
    Filed: August 21, 2002
    Publication date: January 9, 2003
    Applicant: Tularik Inc.
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Patent number: 6458538
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: October 1, 2002
    Assignees: PTC Therapeutics, Inc., Tularik Incorporated
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski